Clinical Trial Update: Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating intracoronary transfer of Wharton’s jelly–derived mesenchymal stem cells in patients with acute myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Wharton’s jelly–derived mesenchymal stem cells (WJ-MSCs) (mesenchymal stem cells)

Snippet

Sponsor: Navy General Hospital, Beijing | Conditions: ST-Elevation Myocardial Infarction | Phase 2 | Status: COMPLETED